Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Patrick Serafino who wrote (1598)	3/31/1998 12:59:00 PM
From: Sigmund	Respond to of 1894

Well I am now long again. What a difference a change in management makes. The conference call after the Sakura deal was dull and the analysts (or so called analysts) asked dull questions. This one was lively with good questions. Looks risky to me in that they are selling off their revenues and their products are unproven in a difficult marketplace. But it looks like they sort of know what they are doing. One negative was the CEO didn't know they had a leasing program....hello!!!! But there will be a stream of good news over the next four months so I think it is a slam dunk as a short term buy. By then, maybe it will be possible to assess the intermediate term prospects. The upside is good so I am again placing my valuable capital at risk. This is the third time I have done this re this company so perhaps three is a charm.

To: Patrick Serafino who wrote (1598)	3/31/1998 1:04:00 PM
From: Frank Buck	Read Replies (2) \| Respond to of 1894

Patrick, Some very interesting comments made during the AccuMed conference call. The Virginia Lab issue was addressed. It is an old issue, and while AccuMed admits to dropping the ball...it was dropped at a point some time ago. An impending strategic alliance with another publicly traded concern is pending announcement. From the conference call, I think we can rule out NeoPath and NeuroMedical. 11-12 buyers are currently looking at AccuMed's non-core microbiology line. Serious bids should be submitted within a six-week period. Patrick, I wouldn't count out the possibility that the share price will not get back to your initial entry period just yet. The reception by the 150 people in attendance at the recent Chicago seminar was encouraging for future sales of the AcCell/TracCell system. The benefit gains in productivity are documented and the strategic alliance with this new publicly traded concern should strengthen those gains. I for one am hoping that it is with a certain Liquid Based Player. Cisco...do we know any of these guys? Any guesses who this strategic partner can be???? Frank